

**FOOD AND DRUG ADMINISTRATION (FDA)  
Center for Drug Evaluation and Research (CDER)  
ANTIVIRAL DRUGS ADVISORY COMMITTEE  
Hilton Hotel, The Maryland Room, Silver Spring, MD  
8:00 a.m. – 12:00 p.m.  
October 20, 2006**

***DRAFT AGENDA***

**Presentations, discussion, and questions will focus on clinical trial design issues in the development of products for the treatment of chronic hepatitis C infection. This meeting is being convened in response to the growing number of products in development for this indication. The primary objectives for the committee deliberations are to discuss issues relating to the identification of appropriate control arms, populations for study, endpoints, and long-term follow-up.**

---

8: 00 a.m.      Call to Order and Opening Remarks

Introduction of Committee

Conflict of Interest Statement

Cicely C. Reese, Pharm.D.  
Designated Federal Officer

8: 15 a.m.      Questions/Discussion

10: 00 a.m.      **Break**

10: 30 a.m.      Questions/Discussion

12: 00 p.m.      **Adjournment**